Skip to content
2000
Volume 22, Issue 2
  • ISSN: 1573-4048
  • E-ISSN: 1875-6581

Abstract

Introduction

Pilomatrixoma, a benign skin tumour originating from hair follicle matrix cells, is characterized by basophilic and shadow cells with calcification and commonly presents as a firm, painless subcutaneous nodule. Polycystic Ovary Syndrome (PCOS) is a complex endocrine disorder affecting 6-12% of women globally, marked by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. It presents with symptoms, such as irregular menstrual cycles, acne, hirsutism, insulin resistance, and increased risks of diabetes, cardiovascular diseases, and infertility.

Case Presentation

A 13-year-old female with upper back swelling was diagnosed with pilomatrixoma. Histopathology revealed basophilic and shadow cells, and lab results indicated elevated lymphocyte counts, reduced monocyte counts, high RBC levels, and microcytic anemia. Ultrasound showed mild polycystic ovarian changes. While pilomatrixoma and PCOS are distinct, shared factors, such as hormonal influences and immune dysregulation, may suggest potential links. Hormonal changes in PCOS, particularly hyperandrogenism, may promote erythropoiesis, contributing to systemic effects observed in pilomatrixoma. Genetic mutations, like CTNNB1, and inflammatory states associated with pilomatrixoma may influence iron metabolism, exacerbating anemia.

Conclusion

No direct correlation exists between pilomatrixoma and PCOS. Shared hormonal and genetic factors warrant further research, but these remain distinct entities with separate clinical management.

Loading

Article metrics loading...

/content/journals/cwhr/10.2174/0115734048353070250514075038
2025-05-21
2026-01-09
Loading full text...

Full text loading...

References

  1. RabaiN.A. AlrababahA. Ba-shammakhS.A. AloqailyA. SalehS.W. Al-OqailyM.M. Pilomatrixoma of the arm: A case report and review of literature.Cureus2023159e4576810.7759/cureus.45768 37872911
    [Google Scholar]
  2. ForbisR. HelwigE.B. Pilomatrixoma (calcifying epithelioma).Arch. Dermatol.196183460661810.1001/archderm.1961.01580100070009 13700704
    [Google Scholar]
  3. AhujaS. ZaheerS. Cytomorphological spectrum of pilomatricoma – A series of 28 cases.Cytopathology202334323223810.1111/cyt.13219 36790316
    [Google Scholar]
  4. OzcanB. Erdogan-DurmusS. Fine-needle aspiration biopsy of pilomatrixoma (Cytological features of six cases histologically approved).J. Cytol.202441316617010.4103/joc.joc_184_23 39239317
    [Google Scholar]
  5. ChaudhuriA. Polycystic ovary syndrome: Causes, symptoms, pathophysiology, and remedies.Obes. Med.20233910048010.1016/j.obmed.2023.100480
    [Google Scholar]
  6. ShrivastavaS. ConigliaroR.L. Polycystic ovarian syndrome.Med. Clin. North Am.2023107222723410.1016/j.mcna.2022.10.004 36759093
    [Google Scholar]
  7. MansourA. MirahmadM. Mohajeri-TehraniM.R. JamalizadehM. HosseinimousaS. RashidiF. AsiliP. Sajjadi-JaziS.M. Risk factors for insulin resistance related to polycystic ovarian syndrome in Iranian population.Sci. Rep.20231311026910.1038/s41598‑023‑37513‑2 37355686
    [Google Scholar]
  8. HossainM.A. Al AminM. HasanM.I. SohelM. AhammedM.A. MahmudS.M.H. RahmanM.R. RahmanM.H. Bioinformatics and system biology approaches to identify molecular pathogenesis of polycystic ovarian syndrome, type 2 diabetes, obesity, and cardiovascular disease that are linked to the progression of female infertility.Inform. Med. Unlocked20223010096010.1016/j.imu.2022.100960
    [Google Scholar]
  9. SiddiquiS. MateenS. AhmadR. MoinS. A brief insight into the etiology, genetics, and immunology of polycystic ovarian syndrome (PCOS).J. Assist. Reprod. Genet.202239112439247310.1007/s10815‑022‑02625‑7 36190593
    [Google Scholar]
  10. DongJ. ReesD.A. Polycystic ovary syndrome: Pathophysiology and therapeutic opportunities.BMJ Med.202321e00054810.1136/bmjmed‑2023‑000548 37859784
    [Google Scholar]
  11. HandlerM.Z. DerrickK.M. LutzR.E. MorrellD.S. DavenportM.L. ArmstrongA.W. Prevalence of pilomatricoma in Turner syndrome: Findings from a multicenter study.JAMA Dermatol.2013149555956410.1001/2013.jamadermatol.115 23426075
    [Google Scholar]
  12. KohI.S. ChoH.J. KimJ.W. Rapidly growing giant pilomatricoma in the right parotid region of a pregnant woman.Arch. Craniofac. Surg.202021317617910.7181/acfs.2019.00710 32630990
    [Google Scholar]
  13. YangJ. ChenC. Hormonal changes in PCOS.J. Endocrinol.20242611e23034210.1530/JOE‑23‑0342 38285626
    [Google Scholar]
  14. WangJ.W. BehnamR. PortoD.A. Possible new defining presentation of mosaic tetrasomy 9p: Multiple and recurrent pilomatrixoma.Dermatol. Online J.2024303610.5070/D330363866 39090039
    [Google Scholar]
  15. StamouM.I. SmithK.T. KimH. BalasubramanianR. GrayK.J. UdlerM.S. Polycystic ovary syndrome physiologic pathways implicated through clustering of genetic loci.J. Clin. Endocrinol. Metab.2024109496897710.1210/clinem/dgad664 37967238
    [Google Scholar]
  16. PhillipsR. StarrM. OrchardD. PurvisD. With it yourself, but you can organise appropriate follow-up.Textbook of Pediatr. Emerg. Med.-E-Book.Elsevier2023407
    [Google Scholar]
  17. YilmazM.A. DuranC. BasaranM. The mean platelet volume and neutrophil to lymphocyte ratio in obese and lean patients with polycystic ovary syndrome.J. Endocrinol. Invest.2016391455310.1007/s40618‑015‑0335‑2 26100531
    [Google Scholar]
  18. SalzmanR. StarekI. FaisalH. TichyT. Pediatric parotideomasseteric pilomatrixoma in children.Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub.2014158460060410.5507/bp.2013.063 24077233
    [Google Scholar]
  19. TedescoS. AdorniM.P. RondaN. CappellariR. MioniR. BarbotM. PinelliS. PlebaniM. BolegoC. ScaroniC. BerniniF. FadiniG.P. CignarellaA. Activation profiles of monocyte-macrophages and HDL function in healthy women in relation to menstrual cycle and in polycystic ovary syndrome patients.Endocrine201966236036910.1007/s12020‑019‑01911‑2 30993600
    [Google Scholar]
  20. WangJ. YinT. LiuS. Dysregulation of immune response in PCOS organ system.Front. Immunol.202314116923210.3389/fimmu.2023.1169232 37215125
    [Google Scholar]
  21. Escobar-MorrealeH.F. Luque-RamírezM. Role of androgen-mediated enhancement of erythropoiesis in the increased body iron stores of patients with polycystic ovary syndrome.Fertil. Steril.20119551730173510.1016/j.fertnstert.2011.01.038 21300335
    [Google Scholar]
  22. AbdelrahmanA. MahmoudA.A. Lamie FanousY. Abd ElhaliemN.G. ElalafH. Impact of erythropoietin and myoinositol versus metformin on insulin resistance in a rat model of polycystic ovary syndrome.Arch. Physiol. Biochem.2024130111210.1080/13813455.2021.1949023 34297646
    [Google Scholar]
  23. AlmashjaryM.N. Reticulocyte hemoglobin content: Advancing the frontiers in iron-deficiency anemia diagnosis and management.J. Appl. Hematol.20241511810.4103/joah.joah_103_23
    [Google Scholar]
  24. CarmelR. Seminars in hematology; Elsevier,200845225234
    [Google Scholar]
  25. BrittenhamG.M. Moir-MeyerG. AbugaK.M. Datta-MitraA. CeramiC. GreenR. PasrichaS.R. AtkinsonS.H. Biology of anemia: A public health perspective.J. Nutr.2023153S7S28(Suppl. 1).10.1016/j.tjnut.2023.07.01837778889
    [Google Scholar]
/content/journals/cwhr/10.2174/0115734048353070250514075038
Loading
/content/journals/cwhr/10.2174/0115734048353070250514075038
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test